Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with -$99.2 million as the latest value for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders fell 9.6% year-over-year to -$99.2 million; the TTM value through Mar 2026 reached -$423.2 million, down 163.82%, while the annual FY2025 figure was -$412.8 million, 161.27% down from the prior year.
  • Net Income towards Common Stockholders hit -$99.2 million in Q1 2026 for Agios Pharmaceuticals, up from -$108.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $947.9 million in Q3 2024 and bottomed at -$112.5 million in Q2 2025.
  • Average Net Income towards Common Stockholders over 4 years is -$15.3 million, with a median of -$95.9 million recorded in 2023.
  • Year-over-year, Net Income towards Common Stockholders surged 1137.97% in 2024 and then tumbled 110.91% in 2025.
  • Agios Pharmaceuticals' Net Income towards Common Stockholders stood at -$95.9 million in 2023, then fell by 0.61% to -$96.5 million in 2024, then fell by 11.93% to -$108.0 million in 2025, then increased by 8.15% to -$99.2 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$99.2 million, -$108.0 million, and -$103.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.